Celgene May Bid for Human Genome, Reuters Says

Celgene Corp. is one of two companies other than GlaxoSmithKline Plc weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.

A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.

(Corrects to say second bidder will propose merger of equals in second paragraph)
Before it's here, it's on the Bloomberg Terminal. LEARN MORE